Table 5.
Effect of RES on HepG2 variant xenograft weight
| Group |
RES (mg/kg) |
n |
Tumor weight/mg |
Inhibitory rate % | Intra-group inhibitory rate% |
| HepG2 | 0 | 4 | 222.50 ± 22.5 | ||
| HepG2 | 15 | 4 | 173.33 ± 33.3a | 22.11 | 22.11 |
| CAV1 | 0 | 4 | 165.50 ± 10.2 a | 25.84 | |
| CAV1 | 15 | 4 | 92.50 ± 15.1b | 58.43 | 44.12 |
| CAVM1 | 0 | 4 | 337.50 ± 20.6 a | -51.68 | |
| CAVM1 | 15 | 4 | 117.50 ± 12.5 b | 47.19 | 65.19 |
| CAVM2 | 0 | 4 | 170.00 ± 18.9 a | 23.61 | |
| CAVM2 | 15 | 4 | 142.50 ± 15.1 b | 35.96 | 16.17 |
| CAVRNAi | 0 | 2 | 247.50 ± 7.07 a | -11.21 | |
| CAVRNAi | 15 | 4 | 230.00 ± 6.80b | -3.37 | 7.07 |
Values are means ± SEM, n = 4.
a. P < 0.05 vs control group.
b. P < 0.05 vs corresponding untreated group (RES at doses of 0 mg/kg)